SENORES Senores Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
Senores Pharmaceuticals delivered a strong Q1 FY26, with consolidated revenue up 72% YoY to INR 138 crores, EBITDA up 60%, and PAT up 95%. Growth was primarily driven by regulated markets and the CDMO-CMO segment. The company achieved positive operating cash flow and continues to expand its product portfolio and manufacturing capabilities, maintaining confidence in its FY26 growth targets despite some margin compression in emerging markets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 101 | 103 | 114 | 138 |
| EBITDA | 23 | 26 | 19 | 34 |
| Net profit | 13 | 16 | 18 | 21 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
